Viewing Study NCT05660967

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:56 AM
Ignite Modification Date: 2026-02-25 @ 12:56 AM
Study NCT ID: NCT05660967
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-02
First Post: 2022-11-29
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
Sponsor: Genmab
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Diffuse Large B-Cell Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Double-hit lymphoma View
None Triple-hit lymphoma View
None Follicular grade 3B View
None T-cell/histiocyte rich LBCL View
None DuoBody® View
None Anti-CD3 View
None Anti-CD20 View
None Subcutaneous View
None Bispecific antibody View
None EPCORE View